American Capital Advisory’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

American Capital Advisory’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-29	Closed	-$2.59K	–	522
2024 Q2	$2.59K	Hold	29	–	–	﹤0.01%	344
2024 Q1	$2.21K	Hold	29	–	–	﹤0.01%	364
2023 Q4	$2.59K	Buy	+29	New	+$2.15K	﹤0.01%	344

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

American Capital Advisory's XBI Position: Q3 2024 in Review

American Capital Advisory sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2024, closing a stake of 29 shares — an estimated $2.59K sold.

American Capital Advisory first reported a position in XBI in Q4 2023 and held it in 3 quarters. The position peaked at $2.59K in Q2 2024. 770 funds tracked by Wall St. Rank hold XBI as of Q3 2024.

American Capital Advisory reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2024 after selling out during the quarter.
American Capital Advisory sold 29 State Street SPDR S&P Biotech ETF shares in Q3 2024, an estimated $2.59K.
American Capital Advisory first reported a position in State Street SPDR S&P Biotech ETF in Q4 2023 and held it in 3 quarters.
American Capital Advisory's State Street SPDR S&P Biotech ETF position peaked at $2.59K in Q2 2024.
770 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2024.

Based on American Capital Advisory's 13F filing for Q3 2024, filed 30 Oct 2024.